TFDP3 Antibody, FITC conjugated

1. Authors established a preclinical model of resistance to induction therapy to examine the functional relevance of TFDP3 to chemoresistance in MRD derived from Jurkat/E6-1. PMID: 27902457
2. TFDP3 can bind to E2F1 molecule to form E2F/TFDP3 complex; and the localizations of TFDP3 and E2F1 molecules and the co-localization were different in different phases of cell cycle in the nucleus and cytoplasm, which indicated that the E2F/TFDP3 complex involved in the process of regulating the cell cycle. PMID: 28797103
3. data highlight that TFDP3 is expressed in breast cancer, that it is a member of the cancer-testis antigen family and that it functions as a regulator in epithelial-mesenchymal transition PMID: 28114432
4. TFDP3 was highly expressed in cancer tissues including prostate cancer tissues.TFDP3 was expressed in coordination with E2F1 in most prostate cancer tissues. PMID: 24406621
5. Data gathered from cell lines, tumorigenicity studies, and primary hepatocellular carcinoma samples demonstrate a negative role of HIF-2alpha in tumors, which is mediated by the TFDP3/E2F1 pathway. PMID: 23212661
6. Data show that TFDP3 upregulates the expression of autophagy gene LC3B and inhibits E2F1-induced apoptosis, and may play an important role in prostate cancer. PMID: 22482402
7. DP-4 downregulating E2F-1 activity and contributes to a new pRb-independent mechanism for regulating cell cycle progression. PMID: 20559320
8. TFDP3, a novel DP protein, inhibits DNA binding and transactivation by E2F PMID: 17062573

Show More

Hide All

HGNC: 24603

OMIM: 300772

KEGG: hsa:51270

STRING: 9606.ENSP00000385461

UniGene: Hs.142908